acute leukemia. acute lymphoblastic leukemia
Conditions
Interventions
Intervention 1: In control group we will use oral busulfan 1mg/kg/d (or 0.8 mg/kg/d venous busulfan)every 6 hour for 16 doses on day -8 to -5 and cyclophosphamide 40 mg/kg/d on days -4 and -2. Interve
Treatment - Drugs
In intervention group we will use cyclophosphamide 40 mg/kg/d on days -8 to -6 and oral busulfan 1mg/kg/d (or 0.8 mg/kg/d venous busulfan)every 6 hour for 16 doses on days -5 to -2.
In control group we will use oral busulfan 1mg/kg/d (or 0.8 mg/kg/d venous busulfan)every 6 hour for 16 doses on day -8 to -5 and cyclophosphamide 40 mg/kg/d on days -4 and -2.
Sponsors
Shiraz University Of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with acute leukemia; patients that are candidate for allogenic Hematopoeitic Stem Cell Transplantation(HSCT) and Exclusion criteria: patients with disease other than acute leukemia; patients with transplantation other than myeloablative HSCT; patients without regular follow up
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function test. Timepoint: before intervention , every other day during hospitalization , weekly till day +100. Method of measurement: IU/L with photometric assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Graft versus host disease and veno-occlusive disease. Timepoint: daily during hospitalization and weekly till day +100 post transplantation. Method of measurement: liver function test and Glucksberg grading. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Nasrin Namdari
Shiraz University Of Medical Sciences
Outcome results
None listed